NCT00359892View on ClinicalTrials.gov

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

November 30, 2008

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

Obatoclax mesylate (GX15-070MS)

60 mg q2wks

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Gemin X
All Listed Sponsors
lead

Gemin X

INDUSTRY

NCT00359892 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter